Nucleix Ltd.

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Our non-invasive EpiCheck platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. Our global team operates from San Diego, United States as well as from Rehovot Israel.